I wonder if we get our 1 st payment from Japan.
AstraZeneca will pay a monthly licence fee for each patient enrolled in the initial study as well as a monthly support fee for the duration of the study. The number of patients in the planned clinical trial and the length of their participation is uncertain.
ResApp does not expect to generate material revenue from the initiative.
Any guess on this income
RAP - dec 2020 qtr revenue and share price prediction (, page-7
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| RAP (ASX) Chart |
Day chart unavailable